



# Chemical Structure of Retro-2, a Compound That Protects Cells against Ribosome-Inactivating Proteins

Jewn Giew Park<sup>1</sup>, Jennifer Nielsen Kahn<sup>2</sup>, Nilgun E. Tumer<sup>2</sup> & Yuan-Ping Pang<sup>1</sup>

<sup>1</sup>Computer-Aided Molecular Design Laboratory, Mayo Clinic, Rochester, MN 55905, USA, <sup>2</sup>Department of Plant Biology and Pathology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 08901, USA.

SUBJECT AREAS:  
CHEMICAL SYNTHESIS  
CHEMICAL BIOLOGY  
DRUG DISCOVERY  
CELL DEATH

Received  
18 June 2012

Accepted  
6 August 2012

Published  
5 September 2012

Correspondence and requests for materials should be addressed to Y.-P.P. (pang@mayo.edu for chemistry) or N.E.T. (tumer@aesop.rutgers.edu for biology)

Shiga-like toxins and ricin are ribosome-inactivating proteins (RIPs) that are lethal to mammals and pose a global health threat. No clinical vaccines or therapeutics currently exist to protect against these RIPs. Two small molecules (Retro-1 and Retro-2) were discovered with high-throughput screening and reported for their protection of cells against RIPs. Of great significance, Retro-2, reported as (*E*)-2-(((5-methylthiophen-2-yl)methylene)amino)-*N*-phenylbenzamide, fully protected mice from lethal nasal challenge with ricin. Herein, we report studies showing that the chemical structure of Retro-2 is ( $\pm$ )-2-(5-methylthiophen-2-yl)-3-phenyl-2,3-dihydroquinazolin-4(1*H*)-one rather than (*E*)-2-(((5-methylthiophen-2-yl)methylene)amino)-*N*-phenylbenzamide. The latter is an achiral molecule that converts spontaneously to the former, which is a racemate and showed cell protection against RIPs. This calls for attention to ( $\pm$ )-2-(5-methylthiophen-2-yl)-3-phenyl-2,3-dihydroquinazolin-4(1*H*)-one as a promising RIP inhibitor and for chemical characterization of drug leads obtained from high-throughput screens.

Shiga-like toxins (Stx1 and Stx2) produced by certain strains of *Escherichia coli* are potent ribosome-inactivating proteins (RIPs)<sup>1</sup> responsible for outbreaks of foodborne disease with significant morbidity and mortality<sup>2</sup>. Ricin, produced by the castor plant *Ricinus communis*, is another potent RIP that has been used for both bioterrorism and the targeted killing of cancerous cells<sup>3</sup>. No US Food and Drug Administration-approved vaccines or therapeutics currently exist to protect against ricin, Shiga-like toxins, or other RIPs.


Small-molecule inhibitors of ricin and Shiga-like toxins have been sought as potential therapeutics for pre- or post-exposure prophylaxis against RIP poisoning. Two small-molecule structures (Retro-1 and Retro-2; Figure 1) have been discovered with high-throughput screening for their cell protection against RIPs<sup>4</sup>. Of great significance, Retro-2 at a concentration of 200 mg/kg demonstrated full protection of mice against a dose of ricin that killed 90% of an unprotected control mouse population<sup>4</sup>.

Using the doorstep approach in search of small-molecule RIP inhibitors that target the catalytic domain of the toxin<sup>5</sup>, we synthesized Retro-2 as a benchmark and found that the reported achiral Retro-2 structure<sup>4</sup> is unstable. Herein, we report our chemical syntheses and cell-based assays showing that the chemical structure of the compound that conferred cell protection activity against RIPs is Retro-2<sup>cycl</sup> (a racemic mixture; Figure 1). This raises a call for attention to Retro-2<sup>cycl</sup> as a promising RIP inhibitor and for chemical characterization of small molecules to be used in biological studies.


## Results

**Chemical structure analysis of Retro-2.** Reaction of 2-amino-*N*-phenylbenzamide with 4-chlorobenzaldehyde in ethanol at room temperature with a catalytic amount of *p*-toluenesulfonic acid reportedly yielded IA4CL (a close analog of Retro-2; Figure 1)<sup>6</sup>. No synthetic procedure has been reported for the commercially available Retro-2, and the vendor ChemBridge (San Diego, CA) provided Retro-2 for the reported biological study<sup>4</sup>. We obtained Retro-2<sup>cycl</sup> in 60% yield using the same reaction conditions reported for the synthesis of IA4CL, and found that these reaction conditions actually produced A4CL (a close analog of Retro-2<sup>cycl</sup>; Figure 1). Evidence that Retro-2<sup>cycl</sup> rather than Retro-2 was the reaction product is found in the chemical shifts of two aliphatic carbon atoms (71.38 and 15.63 ppm) in the carbon NMR spectrum of Retro-2<sup>cycl</sup> because Retro-2 and Retro-2<sup>cycl</sup> have one and two aliphatic carbon atoms, respectively.

We also found that reacting 2-amino-*N*-phenylbenzamide with 5-methylthiophene-2-carbaldehyde in acetic acid at room temperature produced Retro-2<sup>cycl</sup> exclusively in 88% yield. Interestingly, we found that stirring the



**Figure 1** | Chemical structures of Retro-2 and its analogs and a related synthetic scheme.



**Figure 2** | Proton NMR spectra showing spontaneous conversion of Retro-2 to Retro-2<sup>cycl</sup> in neat deuterated methanol over 144 hours.



two reactants in methanol for 1.5 hours at room temperature yielded **Retro-2<sup>cycl</sup>** and **Retro-2**. The latter has a chemical shift of only one aliphatic carbon atom (16.49 ppm) in the carbon NMR spectrum. Our proton NMR spectroscopic study showed that **Retro-2** spontaneously converted to **Retro-2<sup>cycl</sup>** in neat deuterated methanol over a period of 144 hours, as indicated in Figure 2 by the gradual disappearance of the chemical shifts for the imine proton (8.71 ppm) and the methyl proton (2.59 ppm) of **Retro-2** and the gradual and simultaneous appearance of the chemical shifts for the proton at the chiral center (6.26 ppm) and the methyl proton (2.34 ppm) of **Retro-2<sup>cycl</sup>**. The half-life of **Retro-2** is ~24 hours in neat deuterated methanol (Figure 2). In the presence of a catalytic amount of acid, however, the conversion of **Retro-2** to **Retro-2<sup>cycl</sup>** was completed within ~30 minutes.

More conclusively, we purchased **Retro-2**—listed as 2-[(5-methyl-2-thienyl)methylene]amino-*N*-phenylbenzamide with ID 5374762—from ChemBridge and found that the proton and carbon NMR spectra of the product we received were identical to those of **Retro-2<sup>cycl</sup>**. These results indicate that **Retro-2** is unstable and spontaneously converts to **Retro-2<sup>cycl</sup>**.


**Cell-based assays of retro-2<sup>cycl</sup> and A4CL.** To investigate whether **Retro-2<sup>cycl</sup>** is the actual chemical structure associated with cell protection against RIPs, we tested the cell-protection activities of **Retro-2<sup>cycl</sup>** and **A4CL** using a [<sup>35</sup>S]-Met-incorporation-based protein synthesis assay in Vero cells. As shown in Figure 3, the presence of 20 μM **Retro-2<sup>cycl</sup>** moved the dose-response curve of protein synthesis in the presence of ricin or Stx2 to increased Met incorporation, indicating cell protection by **Retro-2<sup>cycl</sup>** against ricin and Stx2. **A4CL** also showed cell protection against both toxins but was slightly less effective than **Retro-2<sup>cycl</sup>**.

## Discussion

The conversion of imines to 2,3-dihydroquinazolin-4(1*H*)-ones is well established in the literature<sup>7–11</sup>. The erroneous characterization of **IA4CL** rather than **A4CL** as the product of the reaction of 2-amino-*N*-phenylbenzamide with 4-chlorobenzaldehyde in ethanol with a catalytic amount of *p*-toluenesulfonic acid was, in our view, probably due to the omission of the crucial carbon NMR spectrum<sup>6</sup>. The abundant literature information on 2,3-dihydroquinazolin-4(1*H*)-one synthesis and our synthetic work described above show unequivocally that **Retro-2** is unstable and spontaneously converts to **Retro-2<sup>cycl</sup>**.

Given that the NMR spectra of **Retro-2** from ChemBridge, which provided **Retro-2** for the reported biological studies<sup>4</sup>, are identical to those of **Retro-2<sup>cycl</sup>** and that **Retro-2<sup>cycl</sup>** and its structurally similar analog **A4CL** protect cells against ricin and Stx2, it is conceivable that **Retro-2<sup>cycl</sup>**—which is a racemate—is the compound responsible for the reported biological activities<sup>4</sup>. In this context, we measured the optical rotations of **Retro-2** from ChemBridge and **Retro-2<sup>cycl</sup>** and found both to be zero. These results further support our assertion that a racemic mixture of **Retro-2<sup>cycl</sup>** produced the reported biological data<sup>4</sup>.

We have previously reported caveats for the use of chemical screens for potential drug leads<sup>5,12</sup>. In a reported virtual screen for farnesyltransferase inhibitors<sup>12</sup>, we found that 6 of 27 compounds purchased from chemical vendors had serious chemical identity or purity issues. In another study of RIP inhibitors<sup>5</sup>, spectroscopic analyses required to confirm the stereochemistry of two chemicals revealed that the stereochemistry of one had been assigned incorrectly by the vendor. In the **Retro-2** report<sup>4</sup>, of two promising chemical structures discovered with high-throughput screening, one appears to have been incompletely characterized by the chemical vendor. These repeated problems raise concerns and call for chemical characterization of leads identified from high-throughput screens.



**Figure 3** | Cell protection against ricin and Stx2 by **Retro-2<sup>cycl</sup>** and **A4CL** in Vero cells.

## Methods

**General description of chemical synthesis.** All commercially available reagents were used as received. <sup>1</sup>H NMR (400 MHz) and <sup>13</sup>C NMR (100 MHz) spectra were recorded on a Mercury 400 spectrometer from Varian (Palo Alto, CA). Chemical shifts are reported in ppm using the solvent peak as an internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, and m = multiplet), coupling constant, and integration. Low-resolution mass spectra (LRMS) were recorded using either a Hewlett Packard 5973 Mass Spectrometer with SIS Direct Insertion Probe (Palo Alto, CA) or a Waters ZQ/EMD 1000 Mass Spectrometer (Milford, MA). High-resolution mass spectra (HRMS) were obtained on a Bruker BioTOF II ESI. IR spectra were obtained on a Thermo Nicolet Avatar 370 FT-IR (Waltham, MA) using a KBr pellet. A Biotage SP-1 (Charlotte, NC) was used for medium pressure liquid chromatography (MPLC) purification using silica gel as the packing material.

**Synthesis of (E)-2-(((5-methylthiophen-2-yl)methylene)amino)-*N*-phenylbenzamide (**Retro-2**).** To a stirred solution of 2-amino-*N*-phenylbenzamide (0.42 g, 2.00 mmol) in methanol (6 mL) at room temperature was added 5-methylthiophene-2-carbaldehyde (214 μL, 2.00 mmol). After 1.5 hours of stirring, the reaction mixture was chilled to −20°C for 1 hour. The resulting yellow short needles were collected via filtration, washed with methanol, and dried under high vacuum to give 0.35 g of yellow powder determined to be a 1:1 mixture of **Retro-2** and **Retro-2<sup>cycl</sup>** using <sup>1</sup>H NMR. The filtrate and washings were combined, concentrated in vacuo, purified with MPLC (silica gel, 100% hexanes to 30% EtOAc-hexanes) to give **Retro-2** (0.16 g) as yellow viscous syrup and 0.11 g of a 1:1 mixture of **Retro-2** and **Retro-2<sup>cycl</sup>**. The estimated yields of **Retro-2** and **Retro-2<sup>cycl</sup>** were 0.39 g (61%) and 0.23 g (36%), respectively. Because **Retro-2** (oil) was cyclized spontaneously to **Retro-2<sup>cycl</sup>** (solid), the spectral data were collected within 30 minutes after MPLC purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.34 (s, 1H), 8.47 (s, 1H), 8.40 (dd, *J* = 1.4, 6.6 Hz, 1H), 7.86 (d, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 7.8 Hz, 1H), 7.51–7.47 (m 1H), 7.40–7.33 (m, 3H), 7.15–7.06 (m, 2H), 6.85 (d, *J* = 3.3 Hz, 1H), and 2.59 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.24 (C=O), 154.42 (C=N), 148.95, 148.52, 139.64, 138.95, 135.67, 132.90, 131.84, 129.25, 129.11, 127.57, 126.97, 124.10, 120.82, 118.98, and 16.49; IR (KBr) ν 3463 (w), 3346 (w), 3060 (w), 1659 (m, C=O), 1608 (s, C=N), and 1538 (m) cm<sup>−1</sup>; LRMS-ESI *m/z* 320 ([M<sup>+</sup>], 100%); HRMS-ESI *m/z* 321.1050 ([M+H]<sup>+</sup>, C<sub>19</sub>H<sub>17</sub>N<sub>2</sub>OS<sup>+</sup> requires 321.1062).



**Synthesis of 2-(5-methylthiophen-2-yl)-3-phenyl-2,3-dihydroquinazolin-4(1H)-one (Retro-2<sup>nd</sup>).** **Method 1:** To a stirred solution of 2-amino-*N*-phenylbenzamide (0.10 g, 0.48 mmol) and a few crystals of *p*-toluenesulfonic acid hydrate in ethanol (3 mL) was added 5-methylthiophene-2-cabdehyde (56.5  $\mu$ L, 0.52 mmol) at room temperature. Yellow precipitates appeared in 10 minutes; the color disappeared in 30 minutes. The precipitates were collected via filtration, and the filter cake was washed with ethanol and dried under high vacuum to give 0.093 g (60%) of Retro-2<sup>nd</sup> as a grey powder. **Method 2:** To a stirred solution of 2-amino-*N*-phenylbenzamide (0.21 g, 1.00 mmol) in acetic acid (3 mL) at room temperature was added 5-methylthiophene-2-cabdehyde (107  $\mu$ L, 1.00 mmol). Thin-layer chromatography showed completion of the reaction in 20 minutes. The solvent was removed in vacuo, and the crude product was purified with MPLC (silica gel, 100% hexanes to 30% EtOAc-hexanes) to give 0.28 g (88%) of Retro-2<sup>nd</sup> as a pale yellow solid. The spectral data of Retro-2<sup>nd</sup> prepared using methods 1 and 2 were identical. mp 152–154 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.03 (d, *J* = 7.8 Hz, 1H), 8.02–7.23 (m, 7H), 6.94 (t, *J* = 7.5 Hz, 1H), 6.70 (d, *J* = 8.2 Hz, 1H), 6.68 (d, *J* = 3.5 Hz, 1H), 6.47–6.46 (m, 1H), 6.20 (d, *J* = 2.3 Hz, 1H), 4.77 (s, 1H), and 2.36 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.56 (C=O), 145.14, 141.24, 140.93, 140.71, 134.07, 129.28, 129.25, 127.21, 127.09, 126.82, 124.58, 120.33, 117.50, 115.58, 71.38, and 15.63; IR (KBr)  $\nu$  3289 (m, N-H), 1637 (s, C=O), 1611 (w), 1505 (m), 1486 (m), and 1387 (m) cm<sup>-1</sup>; LRMS-EI *m/z* 320 ([M<sup>+</sup>], 100%); HRMS-ESI *m/z* 321.1046 ([M+H]<sup>+</sup>, C<sub>19</sub>H<sub>17</sub>N<sub>2</sub>OS<sup>+</sup> requires 321.1062). Anal. calcd for C<sub>19</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>·0.5 H<sub>2</sub>O: C, 69.28; H, 5.20; N, 8.50. Found: C, 69.43; H, 5.23; N, 8.61.

**Conversion experiment of Retro-2 to Retro-2<sup>nd</sup>.** A small amount (~2 mg) of Retro-2 was dissolved in CD<sub>3</sub>OD (1.5 mL), and <sup>1</sup>H NMR spectra were taken every 12 hours. The half-life of Retro-2 to Retro-2<sup>nd</sup> was ~24 hours at room temperature in CD<sub>3</sub>OD.

**[<sup>35</sup>S]-Methionine incorporation assay.** Vero cells were maintained in Dulbecco's modified Eagle medium with 10% fetal calf serum and 1 mM glutamine. The cells were resuspended after trypsin treatment at 4 × 10<sup>4</sup> cells/mL in the same medium, and 0.5 mL of the medium was dispensed into 24-well plates. After 24 hours at 37 °C and 5% CO<sub>2</sub>, the medium was changed to Dulbecco's modified Eagle medium without Met, Gln, or fetal calf serum and equilibrated for 1 hour. An inhibitor solution with a final dimethyl sulfoxide concentration of 0.5% was added to the medium at 25 hours. Ricin or Stx2 was added after 26 hours at varied concentrations. [<sup>35</sup>S]-Met was added 2 hours after ricin exposure or 3 hours after Stx2 exposure. The [<sup>35</sup>S]-Met incorporation was terminated 30 minutes after the Met addition via medium removal and addition of 150  $\mu$ L of 0.2 M KOH to dissolve cells, as described elsewhere<sup>13</sup>. Proteins were precipitated with 10% trichloroacetic acid, harvested on glass fiber filters, and counted. The control incorporation was determined after treatment with 0.5% dimethyl sulfoxide alone. Ricin was purchased from Vector Laboratories (Burlingame, CA). Stx2 was provided by the Phoenix Laboratory (Tufts-NEMC Microbial Products & Services Facility).

- Johannes, L. & Römer, W. Shiga toxins—from cell biology to biomedical applications. *Nat Rev Microbiol* **8**, 105–116 (2010).
- Snedeker, K. G., Shaw, D. J., Locking, M. E. & Prescott, R. J. Primary and secondary cases in *Escherichia coli* O157 outbreaks: a statistical analysis. *BMC Infect Dis* **9**, 144 (2009).
- Audi, J., Belson, M., Patel, M., Schier, J. & Osterloh, J. Ricin poisoning: a comprehensive review. *JAMA* **294**, 2342–2351 (2005).

- Stechmann, B. *et al.* Inhibition of retrograde transport protects mice from lethal ricin challenge. *Cell* **141**, 231–242 (2010).
- Pang, Y.-P. *et al.* Small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstep approach. *PLoS One* **6**, e17883 (2011).
- Liang, Y., Su, B., Zhao, J. & Sun, W. The synthesis of new asymmetric double shift bases containing a new O-amino benzoic acid derivative. *Synth. Commun.* **34**, 3235–3242 (2004).
- Wang, L.-M., Hu, L., Shao, J.-H., Yu, J. & Zhang, L. A novel catalyst zinc(II) perfluorooctanoate [Zn(PFO)<sub>2</sub>]-catalyzed three-component one-pot reaction: synthesis of quinazolinone derivatives in aqueous micellar media. *J. Fluorine Chem.* **129**, 1139–1145 (2008).
- Hisano, T., Ichikawa, M., Nakagawa, A. & Tsuji, M. Studies on organosulfur compounds XII: syntheses and pharmacological activities of 2-heterocyclic substituted 4(3H)-quinazolinones. *Chem. Pharm. Bull.* **23**, 1910–1916 (1975).
- Sattarova, O. E., Vizgunova, O. L. & Voronina, E. V. Synthesis and antimicrobial activity of 1,2-diaryl- and 2,3-diaryl-(2-aryl-3-N-arylamino)-1,2,3,4-tetrahydroquinazolin-4-ones. *Pharm. Chem. J.* **40**, 73–75 (2006).
- Zhang, G. *et al.* Synthesis and crystal structure of a new quinazolinone compound 2,3-dihydro-2-(2-hydroxyphenyl)-3-phenyl-quinazolin-4(1H)-one. *Chinese J. Struct. Chem.* **24**, 783–788 (2005).
- Sattarova, D. E., Kozhevnikov, Y. V., Zalesov, V. S. & Nikulina, S. N. Synthesis and biological activity of novel derivatives of 1,2,3,4-tetrahydroquinazolin-4-one. *Khim.-Farm. Zh.* **18**, 1208–1210 (1984).
- Perola, E. *et al.* Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. *J. Med. Chem.* **43**, 401–408 (2000).
- Jacewicz, M., Feldman, H. A., Donohue-Rolfé, A., Balasubramanian, K. A. & Keusch, G. T. Pathogenesis of Shigella diarrhea. XIV. Analysis of Shiga toxin receptors on cloned HeLa cells. *J. Infect. Dis.* **159**, 881–889 (1989).

## Acknowledgements

This work was supported by the U.S. National Institute of Allergy and Infectious Diseases (1U01AI082120-01). We acknowledge Dr. Dengfeng Dou of the Computer-Aided Molecular Design Laboratory for developing a procedure to prepare Figure 2 in PDF using the MestReNov 7 program (Mestrelab Research, Spain).

## Author contributions

J.G.P. discovered the conversion of Retro-2 to Retro-2<sup>nd</sup>; Y.-P.P., J.G.P., and N.E.T. designed the experiments; J.G.P. and J.N.K. performed the experiments; all authors analyzed the data; Y.-P.P. wrote the paper; all authors contributed with revisions.

## Additional information

**Competing financial interests:** The authors declare no competing financial interests.

**License:** This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

**How to cite this article:** Park, J.G., Kahn, J.N., Tumer, N.E. & Pang, Y.-P. Chemical Structure of Retro-2, a Compound That Protects Cells against Ribosome-Inactivating Proteins. *Sci. Rep.* **2**, 631; DOI:10.1038/srep00631 (2012).